| 李洪波,李 明,刘义安,李小红,俞 嵩.五灵胶囊联合富马酸丙酚替诺福韦片对慢性乙型肝炎患者氧化应激、CD4+CD25+调节性T细胞和血清MMP-1、MMP-2、TIMP-1的影响[J].现代生物医学进展英文版,2024,(3):591-595. |
| 五灵胶囊联合富马酸丙酚替诺福韦片对慢性乙型肝炎患者氧化应激、CD4+CD25+调节性T细胞和血清MMP-1、MMP-2、TIMP-1的影响 |
| Effects of Wuling Capsule Combined with Tenofovir Disoproxil Fumarate Tablets on Oxidative Stress, CD4+CD25+ Regulatory T Cells and Serum MMP-1, MMP-2 and TIMP-1 in Patients with Chronic Hepatitis B |
| Received:June 20, 2023 Revised:July 16, 2023 |
| DOI：10.13241/j.cnki.pmb.2024.03.037 |
| 中文关键词: 五灵胶囊 富马酸丙酚替诺福韦片 慢性乙型肝炎 氧化应激 CD4+CD25+调节性T细胞 MMP-1 MMP-2 TIMP-1 |
| 英文关键词: Wuling capsule Tenofovir disoproxil fumarate tablets Chronic hepatitis B Oxidative stress CD4+CD25+ regulatory T cells MMP-1 MMP-2 TIMP-1 |
| 基金项目:江苏省卫生健康委基金项目（ZD2022041） |
|
| Hits: 380 |
| Download times: 255 |
| 中文摘要: |
| 摘要 目的：探讨五灵胶囊联合富马酸丙酚替诺福韦片对慢性乙型肝炎（CHB）患者氧化应激、CD4+CD25+调节性T细胞和血清基质金属蛋白酶-1（MMP-1）、基质金属蛋白酶-2（MMP-2）、基质金属蛋白酶组织抑制因子-1（TIMP-1）的影响。方法：纳入苏州大学附属传染病医院2021年6月~2022年12月期间收治的CHB患者122例，采用随机数字表法分为对照组（n=61，富马酸丙酚替诺福韦片）和研究组（n=61，五灵胶囊联合富马酸丙酚替诺福韦片）。对比两组疗效、氧化应激指标、CD4+CD25+调节性T细胞、肝功能指标[总胆红素（TBIL）、谷丙转氨酶（ALT）、谷氨酰转肽酶（GGT）]、血清MMP-1、MMP-2、TIMP-1水平和不良反应发生情况。结果：研究组的临床总有效率高于对照组（P<0.05）。两组治疗后丙二醛（MDA）下降，且研究组低于对照组同时间点；超氧化物歧化酶（SOD）升高，且研究组高于对照组同时间点（P<0.05）。两组治疗后CD4+CD25+调节性T细胞下降，且研究组低于对照组同时间点（P<0.05）。两组治疗后MMP-1、MMP-2、TIMP-1下降，且研究组低于对照组同时间点（P<0.05）。两组治疗后TBIL、ALT、GGT下降，且研究组低于对照组同时间点（P<0.05）。两组不良反应总发生率组间对比未见差异（P>0.05）。结论：五灵胶囊联合富马酸丙酚替诺福韦片治疗CHB患者，可有效减轻机体氧化应激，调节CD4+CD25+调节性T细胞和血清MMP-1、MMP-2、TIMP-1水平。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of wuling capsules combine with tenofovir disoproxil fumarate tablets on oxidative stress, CD4+CD25+ regulatory T cells, serum matrix metalloproteinase-1 (MMP-1), matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in patients with chronic hepatitis B (CHB). Methods: 122 CHB patients who were admitted to the Infectious Diseases Hospital Affiliated to Soochow University from June 2021 to December 2022 were enrolled, patients were divided into control group (n=61, tenofovir disoproxil fumarate tablets) and study group (n=61, wuling capsules combined with tenofovir disoproxil fumarate tablets) by random number table method. The efficacy, oxidative stress indexes, CD4+CD25+ regulatory T cells, liver function indexes [total bilirubin (TBIL), alanine aminotransferase (ALT), glutamyl transpeptidase (GGT)], serum MMP-1, MMP-2, TIMP-1 levels and adverse reactions were compared between two groups. Results: The total clinical effective rate in study group was higher than that in control group(P<0.05). The malondialdehyde (MDA) decreased in two groups after treatment, and study group was lower than that of control group at the same time point. Superoxide dismutase (SOD) increased, and study group was higher than that of control group at the same time point(P<0.05). CD4+CD25+ regulatory T cells decreased in two groups after treatment, and study group was lower than that of control group at the same time point(P<0.05). MMP-1, MMP-2 and TIMP-1 decreased in two groups after treatment, and study group was lower than that of control group at the same time point(P<0.05). TBIL, ALT and GGT decreased in two groups after treatment, and study group was lower than that of control group at the same time point (P<0.05). There was no difference in the total incidence of adverse reactions between two groups (P>0.05). Conclusion: Wuling capsule combine with tenofovir disoproxil fumarate tablets in the treatment of CHB patients, which can effectively reduce the body's oxidative stress, regulate CD4+CD25+ regulatory T cells and serum MMP-1, MMP-2, TIMP-1 levels. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
